Безперервна інтестинальна гель-інфузія леводопи-карбідопи (Duodopa/Duopa) — від відбору пацієнтів до моніторингу ускладнень пристрою
Continuous levodopa-carbidopa intestinal gel (LCIG, brand names Duodopa/Duopa) is reserved for advanced Parkinson's disease with motor complications that no longer respond adequately to optimized oral or transdermal regimens. Candidacy screening weighs disease stage, cognitive status, caregiver support, and whether deep brain stimulation (DBS) is medically appropriate or personally preferred, before a device pathway is pursued.
As Parkinson's disease progresses, the striatal dopaminergic terminals that normally buffer and store dopamine are progressively lost. Early in the disease, an oral levodopa dose is absorbed, converted, and stored — smoothing out plasma fluctuations. In advanced disease, this buffering capacity disappears: motor response becomes tightly coupled to plasma levodopa concentration.
The result is a narrowing therapeutic window: oral tablets produce sharp peaks (risking dyskinesia) and troughs ("off" periods with rigidity, bradykinesia, tremor). Because oral levodopa also depends on unpredictable gastric emptying and competition with dietary protein for intestinal transport, absorption becomes erratic — a single missed or delayed gastric emptying event can produce an unpredictable "off" period.
Device-delivered therapies aim to bypass this erratic absorption step entirely, either by continuous jejunal infusion (LCIG) or by replacing dopaminergic pharmacology with continuous electrical modulation of basal ganglia circuits (DBS).
Candidacy assessment for LCIG typically considers:
• Motor fluctuations: ≥1–2 hours per day of "off" time or troublesome dyskinesia despite optimized oral polypharmacy • Levodopa responsiveness: motor symptoms must still respond to levodopa — LCIG intensifies delivery of the same drug class, it does not treat levodopa-unresponsive features • Cognitive and psychiatric status: patient or caregiver must manage a pump, cassette changes, and tube care; significant dementia or unmanaged psychiatric illness may favor LCIG over DBS (fewer stimulation-related neuropsychiatric risks) or may exclude both • Age and surgical risk: DBS involves intracranial electrode placement; LCIG requires only an abdominal endoscopic procedure, making it an option for patients who decline or are poor candidates for brain surgery • Patient preference: some patients prioritize avoiding any intracranial procedure; others prioritize avoiding a permanent externalized pump and tube
Both pathways target the same underlying problem — pulsatile, unreliable dopaminergic stimulation — from different angles: pharmacokinetic smoothing (LCIG) versus circuit-level modulation (DBS).
Neither DBS nor LCIG is curative or disease-modifying — both are advanced symptomatic strategies for motor fluctuations once oral regimens are exhausted. The choice between them is individualized, shared-decision-making territory involving movement disorder specialists, neurosurgeons, and the patient's support system.
Before a permanent PEG-J system is surgically placed, a temporary nasojejunal (NJ) tube is passed through the nose, down the esophagus, through the stomach, and into the jejunum under fluoroscopic or endoscopic guidance. The same levodopa-carbidopa gel is infused for several days to confirm meaningful clinical benefit — a reversible, low-risk trial before committing to a permanent device.
Committing directly to a permanent PEG-J tube without first confirming benefit would expose patients to an invasive gastrostomy procedure and its complication risks without evidence the therapy will actually help. The NJ trial de-risks this decision:
• Confirms the patient tolerates continuous jejunal drug delivery (some patients experience abdominal discomfort, nausea, or tube-related irritation) • Confirms meaningful reduction in "off" time and dyskinesia using structured motor diaries and clinician-rated scales (e.g., UPDRS Part III, "on/off" diaries) • Allows dose titration of the continuous infusion rate and morning bolus in a low-risk, fully reversible setting • Screens for practical barriers: caregiver ability to manage the pump, cognitive capacity to operate device controls, home environment suitability
Only patients who show clear, reproducible motor benefit during the NJ trial proceed to permanent PEG-J placement — reserving the more invasive procedure for those most likely to benefit long-term.
The NJ tube is a thin, flexible catheter advanced transnasally:
• Placement: passed through a nostril, down the pharynx and esophagus, through the stomach, and across the pylorus into the proximal jejunum — positioning is confirmed radiographically • Connection: the external end connects to the same portable infusion pump used in the permanent system, running the identical levodopa-carbidopa intestinal gel formulation • Titration window: infusion rate and morning bolus are adjusted daily based on patient-reported motor state, mirroring how the permanent system will later be tuned • Tolerability check: nasal/pharyngeal irritation, dislodgement with coughing or nose-blowing, and cosmetic externalization are all things patients experience firsthand — informative for the shared decision about moving to a permanent, internally anchored tube
Because the NJ tube is not surgically fixed, it is more prone to accidental removal than the permanent PEG-J system — reinforcing that this stage is explicitly a trial, not the definitive therapy.
Once the NJ trial confirms benefit, a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) is placed. An endoscopically guided gastrostomy port through the abdominal wall anchors a tube whose distal extension threads through the stomach and into the jejunum, connecting externally to a small, belt-worn pump that delivers gel continuously during waking hours.
The permanent delivery system has three connected components:
1. Gastrostomy port: a low-profile port sits flush against the abdominal wall, secured internally by a bumper against the stomach wall — placed endoscopically under conscious sedation, analogous to a standard feeding-tube gastrostomy
2. Jejunal extension tube: a thinner catheter passes through the gastrostomy port, through the stomach lumen, across the pylorus, and terminates in the jejunum — this is the segment that actually delivers drug, bypassing the stomach
3. Portable infusion pump: a compact, programmable pump worn on a belt or in a small bag connects to the external tube each morning; it delivers a morning bolus dose followed by a continuous basal infusion for the remainder of the waking day, then is disconnected at bedtime
The gel itself is a viscous carboxymethylcellulose suspension of levodopa and carbidopa, supplied in single-day cassettes loaded directly into the pump — carbidopa is co-formulated to inhibit peripheral dopa-decarboxylase, reducing peripheral conversion and side effects, exactly as in oral carbidopa-levodopa combinations.
Oral levodopa's erratic absorption in advanced PD stems largely from variable gastric emptying — delayed emptying (itself common in PD due to autonomic dysfunction) leaves levodopa sitting in the stomach, degraded by gastric acid and delayed in reaching its small-intestinal absorption site. Levodopa is absorbed almost exclusively in the proximal small intestine via the large neutral amino acid transporter (LAT1).
By infusing gel directly into the jejunum, the delivery system:
• Eliminates the variable, PD-affected step of gastric emptying entirely • Delivers levodopa directly to its main absorption site at a controlled, steady rate • Allows fine, continuous titration (mg/hour) rather than discrete oral pulses • Still requires attention to dietary protein timing, since LAT1 is shared with dietary amino acids and competitive inhibition can still occur at the level of intestinal transport
The system separates two pharmacokinetic problems that afflict oral dosing: unpredictable gastric emptying (solved by jejunal placement) and pulsatile dosing intervals (solved by continuous rather than intermittent delivery). Both must be addressed for stable plasma levels.
The pharmacological rationale for LCIG rests on the "continuous dopaminergic stimulation" hypothesis: intermittent, pulsatile levodopa dosing produces swings between under- and over-stimulation of striatal dopamine receptors, which is thought to drive both motor fluctuations and dyskinesia over time. Continuous jejunal infusion aims to hold plasma levodopa within a narrower therapeutic band across the day.
Normal, non-parkinsonian dopaminergic neurotransmission is tonic and continuous — striatal dopamine levels are buffered by presynaptic terminals that store and gradually release dopamine, smoothing out any variability in supply. As nigrostriatal neurons degenerate in Parkinson's disease, this buffering capacity is progressively lost, and postsynaptic striatal neurons become exposed directly to however dopamine (or its precursor levodopa) happens to be delivered.
With standard oral dosing, plasma levodopa rises and falls sharply between doses — spiking after each tablet, then falling as the drug is metabolized (half-life of roughly 60–90 minutes). In advanced disease without buffering capacity, postsynaptic receptors experience this as alternating over-stimulation (contributing to dyskinesia at peak concentrations) and under-stimulation ("off" periods as levels trough below the therapeutic threshold).
Continuous infusion is designed to keep plasma levodopa within a narrower band — high enough to maintain the "on" state, but without the sharp peaks associated with dyskinesia — by replacing discrete pulses with steady-state delivery, topped with a morning bolus to reach therapeutic levels quickly at the start of the day.
Two levers are used to titrate the infusion, mirrored in this simulator's sliders:
• Morning bolus dose: a larger initial dose delivered over a short period at the start of the infusion day, intended to bring the patient from an overnight "off" state into the "on" state quickly — analogous to a loading dose
• Continuous infusion rate (mg/hour): the steady-state basal rate maintained for the remainder of the waking day, titrated up or down based on the patient's motor response — too low and "off" symptoms re-emerge; too high and peak-dose dyskinesia can appear even without discrete pulses
Extra bolus doses can also be manually triggered for breakthrough "off" episodes, but frequent extra boluses generally prompt a re-titration of the base continuous rate rather than being used as a long-term workaround.
The figures reported by this simulator (plasma stability, "off"-time reduction, dyskinesia reduction) are simplified, illustrative functions of these two parameters for teaching purposes — actual titration is individualized by a movement disorder specialist using motor diaries and exam findings, not a fixed formula.
Clinical trials and long-term registries of LCIG consistently show substantial reductions in "off" time and troublesome dyskinesia compared with optimized oral therapy in advanced Parkinson's disease. These benefits come with a distinct complication profile tied to the device itself — tube and stoma-related issues rather than systemic drug toxicity — requiring structured, ongoing monitoring.
Randomized and open-label studies of LCIG versus optimized oral therapy in advanced Parkinson's disease have reported:
• Meaningful reduction in daily "off" time — patients spend measurably more of their waking day in a well-controlled "on" state • Reduction in troublesome dyskinesia — because plasma levels are held within a narrower band, the sharp peaks associated with peak-dose dyskinesia are blunted • Improvements in quality-of-life measures related to motor function, though device burden (wearing a pump, tube care) can offset some quality-of-life gains for certain patients • Benefits are generally sustained over long-term follow-up in registry studies, though continued dose titration is often needed as the underlying disease progresses
These benefits are specifically attributable to the pharmacokinetic smoothing described in Stage 4 — the drug itself (levodopa-carbidopa) is unchanged from oral therapy; only its delivery pattern differs.
Because LCIG relies on a permanently implanted tube and external pump, its complication profile is dominated by device and procedure-related events rather than new drug toxicity:
• Tube dislodgement or migration: the jejunal extension can migrate back into the stomach, requiring endoscopic repositioning; a leading cause of unplanned interruptions in therapy • Tube occlusion or kinking: the gel is viscous, and blockages can occur, causing an abrupt loss of drug delivery and return of motor symptoms • Peristomal infection or granulation tissue: local skin and stoma-site care is required; infection can range from superficial cellulitis to, rarely, more serious intra-abdominal complications • Peritonitis: an uncommon but serious complication requiring urgent evaluation if the tube tract is compromised • Polyneuropathy: reported in a subset of LCIG patients, thought to relate to metabolic effects of sustained high-dose levodopa exposure (e.g., vitamin B12/homocysteine pathway effects) — periodic neurological and laboratory monitoring is recommended • Weight loss: can occur, related both to the underlying disease and to the intervention itself
Structured follow-up — combining device checks, stoma care, periodic laboratory monitoring, and neurological assessment — is a core part of ongoing LCIG management, not a one-time consideration at implantation.
The clinical trade-off of LCIG is characteristic of many advanced device-based therapies: substantial, well-documented improvement in the target symptoms (motor fluctuations, dyskinesia) in exchange for a new category of risk — mechanical and procedural device complications — that did not exist with oral therapy and must be actively monitored for the life of the device.